Description: Bladder cancer with bladder tissue array, including urothelial carcinoma,squamous cell carcinoma, adenocarcinoma and normal tissue, pathololy grade, TNM and clinical stage (AJCC 8.0), 12 case/24 cores (1.5mm), replacing BL243

Description: Bladder cancer with bladder tissue array, including urothelial carcinoma, squamous cell carcinoma, adenocarcinoma and normal tissue, TNM/Stage, 48 cases/48 cores (core size 2.0 mm), replacing BL481d

Description: Bladder cancer with bladder tissue array, including TNM and clinical stage, 80 cases/80 cores

Description: Bladder cancer with bladder tissue array, including pathology grade, TNM and clinical stage, 12 cases/24 cores, replacing T124b

Description: Bladder cancer with bladder tissue test array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T121a

Description: Multiple bladder carcinoma with bladder tissue array, including pathology grade, TNM and clinical stage, 75 cases/150 cores, replacing BL1501

Description: Bladder cancer tissue array for antibody screening, including TNM, clinical stage and pathology grade, 25 cases/100 cores

Description: Bladder cancer tissue array with normal bladder tissue, including pathology grade, TNM and clinical stage, 48 cases/48 cores, replaced by BL481c

Description: Bladder tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Description: Bladder tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Description: Rabbit Polyclonal Uroplakin 3A (Bladder Carcinoma Marker) Antibody. Validated in WB and tested in Human.

Description: Bladder cancer with bladder tissue array (2016 WHO classification), including pathology grade, TNM and clinical stage (AJCC 7th edition), 64 cases/192 cores, replacing BL208

Description: Bladder invasive urothelial carcinoma with matched bladder tissue array, including pathology grade, TNM and clinical stage, 12 cases/24 cores (1.5mm), replacing BL244a

Description: Bladder cancer tissue array with matched adjacent normal bladder tissue, including TNM and pathology grade, 24 cases/63 cores

Description: Rat

Description: Rat bladder fibroblasts, 3-week Wistar rat

Description: Human bladder tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human bladder tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated bladder tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated bladder tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Description: Bladder urothelial carcinoma with matched cancer adjacent bladder tissue array, including TNM and clinical stage, 10 cases/24 cores, replacing BL241a

Description: Bladder disease spectrum (urocystic cancer progression) with bladder tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores

Description: Rabbit